MedTrace Logo

Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implications

NCT03960034 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-04-15

No results posted yet for this study

Summary

LUCAX01 is a cohort study with patients with advanced NSCLC in tobacco users. in this study, patients will be submitted to baseline physical tests, blood and biopsy sample collection, and the main objective is to study the functional and prognostic implications of cachexia and to validate skeletal muscle dysfunction markers.

Conditions

  • NSCLC Stage IV

Sponsors & Collaborators

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Principal Investigators

  • Gilberto de Castro Junior, MD, PhD · Instituto do Câncer do Estado de São Paulo - FMUSP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-10
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03960034 on ClinicalTrials.gov